FluoGuide AS
96X
Company Profile
Business description
FluoGuide AS is a clinical-stage biotechnology company focused on developing drugs that maximize surgical outcomes by making cancer fluorescent. Its technology includes uPAR, which is part of a proteolytic system, and FG001, a product injected into the patient's vein prior to surgery.
Contact
Titanhus, Titangade 9-13
CopenhagenDK-2200
DNKT: +45 31226660
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
7
Stocks News & Analysis
stocks
ASX healthcare share undervalued post earnings
Short term headwinds mask long term value opportunity.
stocks
ASX energy share sees 363% increase in dividend
Geopolitical tensions drive strong profit and dividends for oil refiner.
stocks
Wide moat share remains cheap despite rising costs
Higher costs weigh on profits but stronger sales trends support long term outlook.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,338.80 | 54.50 | -0.58% |
| CAC 40 | 8,477.35 | 38.15 | 0.45% |
| DAX 40 | 26,244.16 | 21.98 | -0.08% |
| Dow JONES (US) | 53,577.40 | 160.24 | 0.30% |
| FTSE 100 | 10,881.38 | 4.78 | -0.04% |
| HKSE | 25,652.97 | 141.87 | 0.56% |
| NASDAQ | 26,151.30 | 171.11 | 0.66% |
| Nikkei 225 | 66,262.16 | 405.73 | 0.62% |
| NZX 50 Index | 14,013.21 | 20.49 | 0.15% |
| S&P 500 | 7,677.28 | 24.42 | 0.32% |
| S&P/ASX 200 | 9,127.80 | 55.90 | -0.61% |
| SSE Composite Index | 3,912.52 | 23.08 | 0.59% |